NorthRock Partners’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$602K Buy
12,559
+5,533
+79% +$238K 0.01% 400
2026
Q1
$258K Buy
7,026
+838
+14% +$39.7K ﹤0.01% 568
2025
Q4
$315K Buy
6,188
+851
+16% +$43.5K 0.01% 470
2025
Q3
$296K Buy
5,337
+467
+10% +$27.3K 0.01% 702
2025
Q2
$336K Buy
+4,870
New +$331K 0.01% 508
2024
Q3
Sell
-2,241
Closed -$320K 857
2024
Q2
$320K Buy
2,241
+184
+9% +$24.4K 0.01% 452
2024
Q1
$272K Buy
+2,057
New +$245K 0.01% 503
2023
Q4
Sell
-2,781
Closed -$253K 753
2023
Q3
$253K Buy
+2,781
New +$245K 0.03% 274

Other funds holding NVO

NorthRock Partners's NVO Position: Q2 2026 in Review

NorthRock Partners increased its Novo Nordisk (NVO) stake by 79% in Q2 2026, buying an estimated $238K and bringing the position to 12,559 shares worth $602K. The position accounts for 0.01% of the portfolio, ranked #400.

NorthRock Partners first reported a position in NVO in Q3 2023 and has held it in 8 quarters since. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • NorthRock Partners held 12,559 shares of Novo Nordisk worth $602K as of Q2 2026.
  • NorthRock Partners bought 5,533 Novo Nordisk shares in Q2 2026, an estimated $238K.
  • Novo Nordisk made up 0.01% of NorthRock Partners's portfolio in Q2 2026, its #400 holding.
  • NorthRock Partners first reported a position in Novo Nordisk in Q3 2023 and has held it in 8 quarters since.
  • 1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on NorthRock Partners's 13F filing for Q2 2026, filed 11 Aug 2026.